NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
0.5400
+0.0050 (0.93%)
At close: May 22, 2026, 4:00 PM EDT
0.5205
-0.0195 (-3.61%)
After-hours: May 22, 2026, 7:21 PM EDT
NEXGEL Revenue
NEXGEL had revenue of $2.65M in the quarter ending March 31, 2026, a decrease of -5.56%. This brings the company's revenue in the last twelve months to $11.26M, up 10.14% year-over-year. In the year 2025, NEXGEL had annual revenue of $11.42M with 31.46% growth.
Revenue (ttm)
$11.26M
Revenue Growth
+10.14%
P/S Ratio
0.41
Revenue / Employee
$592,895
Employees
19
Market Cap
4.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.42M | 2.73M | 31.46% |
| Dec 31, 2024 | 8.69M | 4.60M | 112.47% |
| Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
| Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
| Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
| Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
| Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
| Dec 31, 2018 | 2.21M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 85.53M |
| Retractable Technologies | 37.15M |
| Bionano Genomics | 28.74M |
| Jin Medical International | 20.69M |
| Nephros | 19.12M |
| Milestone Scientific | 8.90M |
| Lucyd | 2.98M |
| Femasys | 2.38M |
NXGL News
- 3 days ago - NexGel announces data from institutional review board clinical study - TheFly
- 3 days ago - NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration - GlobeNewsWire
- 7 days ago - NEXGEL Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - NEXGEL Quarterly report: Q1 2026 - Filings
- 9 days ago - NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical - GlobeNewsWire
- 10 days ago - NEXGEL To Report First Quarter 2026 Financial Results on May 15th - GlobeNewsWire
- 16 days ago - NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors - GlobeNewsWire
- 25 days ago - NexGel appoints Ian Blackman as CFO - TheFly